Before you sell to, join or invest in Matinas BioPharma Holdings, Inc.
MentionFox check on Matinas BioPharma Holdings, Inc.: only 2 sources on file so far (checked 5 November 2026). Run a full check before you rely on it. mentionfox.com/c/funding/matinas-biopharma-holdings-inc-form-d-25000001
Check Matinas BioPharma Holdings, Inc. before you sell to, join or invest Free, no sign-up: every record on file, each linked to its source.
What do you want to do about Matinas BioPharma Holdings, Inc.?
Based on the records MentionFox holds for this company. No flag is not a clearance.
Matinas BioPharma Holdings, Inc. filed a Form D with the Securities and Exchange Commission on 2025-02-19.
Matinas BioPharma Holdings, Inc. filed a Form D notice of an exempt securities offering with the SEC on February 19, 2025. The filing reports $1.65M sold. Its industry group is Biotechnology. It names Jerome Jabbour (Executive Officer, Director), Keith Kucinski (Executive Officer), Eric Ende (Director) (SEC Form D, February 19, 2025).
125 companies raised this week.
Companies that just raised money, and the people to call. Before you unlock: the company, the amount, the date and what is inside (for example 2 people, phone, LinkedIn). After: the officers and directors the filing names with their roles, how to reach the company, and a person's email only when we found one.
| Andersen Aggregator LLC | $1.9B | Business services |
| AT Umbrella LLC | $1.9B | Business services |
| Legora, Inc. | $221M | AI and software |
| MD INVESTMENT LLC | $169M | Business services |
| Serval Inc. | $149M | AI and software |
Is this your company?
Sell to companies like Matinas BioPharma Holdings, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2025-02-19 · the record
Pitching, partnering or investing alongside them? See who really runs and owns Matinas BioPharma Holdings, Inc.
Free to see. No signup.
More on the people and the money behind Matinas BioPharma Holdings, Inc., from the filings we hold.
Biotechnology raises by companies based in New Jersey, filed within 90 days of this one, largest first.
Get an email when Matinas BioPharma Holdings, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when Matinas BioPharma Holdings, Inc. raises, hires or launches. No email unless you switch it on.
Watch Matinas BioPharma Holdings, Inc. →Get the full cited report on Matinas BioPharma Holdings, Inc.
What the filing shows about Matinas BioPharma Holdings, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Matinas BioPharma Holdings, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
The filing gives Matinas BioPharma Holdings, Inc.'s address as 1545 Route 206 South, Suite 302, Bedminster, NJ 07921.
Saved here on this device in the meantime, so nothing is lost either way.
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Order the Full Report on Matinas BioPharma Holdings, Inc. See pricing
Matinas BioPharma Holdings, Inc. is a registered filer with the SEC (CIK 1582554) and has filed since 2025-02-19. 1 filing is on record, the latest on 2025-02-19.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
Matinas BioPharma Holdings, Inc.'s Form D of 2025-02-19 names Jerome Jabbour, Keith Kucinski, Eric Ende and 4 more as its officers, directors or promoters.
Its new offerings report $1.65M sold across 1 offering, as its own filings state.
Trailing twelve months. 765 filings in Biotechnology, totalled by week.
Some proceeds to be used for general working capital purposes.
Jerome Jabbour is named as Executive Officer and Director on the Form D that Matinas BioPharma Holdings, Inc. filed with the SEC on 19 February 2025, one of 7 people that filing names.
Keith Kucinski is named as Executive Officer on the Form D that Matinas BioPharma Holdings, Inc. filed with the SEC on 19 February 2025, one of 7 people that filing names.
Eric Ende is named as Director on the Form D that Matinas BioPharma Holdings, Inc. filed with the SEC on 19 February 2025, one of 7 people that filing names.
Robin Smith is named as Director on the Form D that Matinas BioPharma Holdings, Inc. filed with the SEC on 19 February 2025, one of 7 people that filing names.
Evelyn D'An is named as Director on the Form D that Matinas BioPharma Holdings, Inc. filed with the SEC on 19 February 2025, one of 7 people that filing names.
Natasha Giordano is named as Director on the Form D that Matinas BioPharma Holdings, Inc. filed with the SEC on 19 February 2025, one of 7 people that filing names.
Matthew Wikler is named as Director on the Form D that Matinas BioPharma Holdings, Inc. filed with the SEC on 19 February 2025, one of 7 people that filing names.
7 people named on the filing — 2 holding an executive role and 5 as directors only.
Named as of the 2025-02-19 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about Matinas BioPharma Holdings, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Matinas BioPharma Holdings, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Matinas BioPharma Holdings, Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Matinas BioPharma Holdings, Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind Matinas BioPharma Holdings, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.
Each opens in a new tab, filled in for Matinas BioPharma Holdings, Inc.. With no account yet, you sign up free and land on the result.
Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.
https://mentionfox.com/funding/matinas-biopharma-holdings-inc-form-d-25000001